Publications by authors named "E W Gabrielson"
Article Synopsis
- Ductal carcinoma in-situ (DCIS) is a non-invasive breast cancer type that makes up about 25% of breast cancer cases, but it often leads to unnecessary aggressive treatment despite many cases never progressing to invasive cancer.
- A study analyzed 197 breast tissue samples to explore molecular changes in DCIS, using techniques like mRNA expression and DNA analysis to compare progressing versus non-progressing cases.
- The research found significant molecular differences among DCIS subtypes and between DCIS and invasive breast cancer, highlighting the complexity of DCIS and the need for more tailored approaches to assess risk and treatment.
Pathologic response is an endpoint in many ongoing clinical trials for neoadjuvant regimens, including immune checkpoint blockade and chemotherapy. Whole-slide scanning of glass slides generates high-resolution digital images and allows for remote review and potential measurement with image analysis tools, but concordance of pathologic response assessment on digital scans compared with that on glass slides has yet to be evaluated. Such a validation goes beyond previous concordance studies, which focused on establishing surgical pathology diagnoses, as it requires quantitative assessment of tumor, necrosis, and regression.
View Article and Find Full Text PDFContext.—: Autopsies performed on COVID-19 patients have provided critical information about SARS-CoV-2's tropism, mechanisms of tissue injury, and spectrum of disease.
Objective.
Article Synopsis
- * The CheckMate 816 trial assessed the effectiveness of this treatment approach, measuring residual viable tumor (RVT) percentages and their impact on EFS as an exploratory analysis, finding that less than 5% RVT significantly improved EFS compared to higher levels.
- * Results indicate that the percentage of RVT could serve as a reliable predictor of survival outcomes, suggesting that further exploration of RVT thresholds in lung cancer and other cancers is needed for treatment optimization. *
Background: Combination therapies that aim to improve the clinical efficacy to immune checkpoint inhibitors have led to the need for non-invasive and early pharmacodynamic biomarkers. Positron emission tomography (PET) is a promising non-invasive approach to monitoring target dynamics, and programmed death-ligand 1 (PD-L1) expression is a central component in cancer immunotherapy strategies. [F]DK222, a peptide-based PD-L1 imaging agent, was investigated in this study using humanized mouse models to explore the relationship between PD-L1 expression and therapy-induced changes in cancer.
View Article and Find Full Text PDF